The Royal's Institute of Mental Health Research, Royal Ottawa Mental Health Centre, 1145 Carling Avenue, Ottawa, ON, K1Z 7K4, Canada.
Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
Psychopharmacology (Berl). 2022 Jul;239(7):2155-2169. doi: 10.1007/s00213-022-06090-z. Epub 2022 Mar 28.
Deficits in early auditory sensory processing in schizophrenia have been linked to N-methyl-D-aspartate receptor (NMDAR) hypofunction, but the role of NMDARs in aberrant auditory sensory gating (SG) in this disorder is unclear. This study, conducted in 22 healthy humans, examined the acute effects of a subanesthetic dose of the NMDAR antagonist ketamine on SG as measured electrophysiologically by suppression of the P50 event-related potential (ERP) to the second (S2) relative to the first (S1) of two closely paired (500 ms) identical speech stimuli. Ketamine induced impairment in SG indices at sensor (scalp)-level and at source-level in the auditory cortex (as assessed with eLORETA). Together with preliminary evidence of modest positive associations between impaired gating and dissociative symptoms elicited by ketamine, tentatively support a model of NMDAR hypofunction underlying disturbances in auditory SG in schizophrenia.
精神分裂症早期听觉感觉处理缺陷与 N-甲基-D-天冬氨酸受体 (NMDAR) 功能低下有关,但 NMDAR 在该障碍中异常听觉感觉门控 (SG) 中的作用尚不清楚。本研究在 22 名健康人类中进行,检查了亚麻醉剂量的 NMDAR 拮抗剂氯胺酮对 SG 的急性影响,这是通过抑制 P50 事件相关电位 (ERP) 来测量的,与两个紧密配对的 (500ms) 相同语音刺激的第二个 (S2) 相对于第一个 (S1)。氯胺酮在头皮水平和听觉皮层的源水平 (通过 eLORETA 评估) 上导致 SG 指数受损。与氯胺酮引起的门控障碍与分离症状之间存在适度正相关的初步证据一起,暂时支持 NMDAR 功能低下模型,该模型是精神分裂症中听觉 SG 障碍的基础。